Federal budget issues
2026 · 1st Quarter (Jan 1 - Mar 31)
NOVARTIS
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- NOVARTIS
- Filing UUID
- 386dcc7b-f394-442e-94bc-d6380b1ee19e
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
MINI Act, IRA, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies, supply chain, drug pricing and drug discount programs in federal programs, international drug reference pricing
bio pharmaceutical reimbursement issues, IRA
tariffs
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.